Real Chemistry @ the Fierce Biotech Summit
As the biotech sector looks ahead to re-emerge with renewed vigor in the coming year, it is crucial for companies to get ahead of the curve by effectively communicating the value of scientific advancements, crafting a growth-focused corporate narrative, navigating regulatory complexities and engaging with the funding community at the right moments. Real Chemistry recently joined leaders from across the industry at the Fierce Biotech Summit in Boston to discuss how biotech companies can position themselves for success in this rapidly evolving landscape.
Real Chemistry Deputy Group President Mary Claire Duch was joined in a panel discussion by Kathleen Tregoning, Chief Corporate Affairs Officer at Cerevel Therapeutics, and Alethia Young, Chief Financial Officer at Bicycle Therapeutics, that brought together expert perspectives from the biotech sector, the investment community and agency to discuss the pivotal role of strategic communications. With so much noise in the landscape, the group noted that having a concise, compelling narrative and being able to communicate in a way that really resonates across stakeholder groups is more important than ever for biotech companies at all stages.
See below for an interview with Fierce Biotech publisher Rececca Willumson, Mary Clare Duch and Kathleen Tregoning as a supplement to this engaging panel discussion.
type: entry-hyperlink id: 7gDbIkfOv5OfUkvX1xilD4
Want more insights on the people, stories and ideas that are changing healthcare into what it should be? Subscribe to our Healthcare Connection newsletter and get transformative ideas delivered to your inbox every month.
